Related Experiment Video

Updated: Aug 8, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

[Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2]

Yan-ming Lu1, Shu-lan Zhang, Li-rong Meng

  • 1Department of Gynecology and Obstetrics, Second Affiliated Hospital, China Medical University, Shenyang 110004, China.

Zhonghua Yi Xue Za Zhi
|May 10, 2006
PubMed
Abstract

Insights

RNA interference targeting the HER-2 gene effectively suppressed its expression in ovarian cancer cells. This approach enhanced cisplatin sensitivity and induced apoptosis, offering a new therapeutic strategy for ovarian cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Therapy

Context:

  • Human ovarian carcinoma is a significant cause of cancer-related mortality.
  • The HER-2 gene is frequently overexpressed in ovarian cancers, correlating with poor prognosis.
  • Targeting HER-2 offers a potential therapeutic strategy for ovarian cancer.

Purpose:

  • To investigate the efficacy of RNA interference (RNAi) targeting the HER-2 gene in human ovarian carcinoma cells.
  • To assess the impact of HER-2 gene suppression on cancer cell biological traits, including apoptosis and chemosensitivity.

Summary:

  • Synthesized HER-2 specific siRNA was used to transfect SKOV-3 human ovarian carcinoma cells.
  • HER-2 mRNA and protein expression were significantly reduced post-transfection, confirmed by RT-PCR and Western blotting.
  • Flow cytometry and MTT assays demonstrated increased apoptosis and enhanced chemosensitivity to cisplatin in HER-2 siRNA-treated cells.

Impact:

  • Successfully suppressed HER-2 expression in ovarian cancer cells.
  • Induced significant apoptosis and increased sensitivity to cisplatin.
  • Highlights HER-2 siRNA as a promising therapeutic modality for human ovarian cancer treatment.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...